Sulfasalazine
Especificaciones
599-79-1Número CAS
2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acidNombre IUPAC
C18H14N4O5SFórmula química
398.4 g/molPeso molecular
sulfasalazine; 599-79-1; Salicylazosulfapyridine; Azulfidine; Salazosulfapyridine; Sulphasalazine; Salazopyrin; Benzosulfa; Sulcolon; Asulfidine; Azopyrine; Salazopyridin; Accucol; Azopyrin; Salisulf; Salazopiridazin; Reupirin; Colo-Pleon; Salazosulfapyridin; w-t Sasp oral; Sulfasalazin; Sulfasalazina; Sulfasalazinum; Sulfazalazine; Azulfidine EN-tabs; Sas-500; Azulfidine EN; SASP; Salazosulfapiridina; Salazosulfapyridinum; (E)-2-hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; S.A.S.-500; 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid; NSC 667219; 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene; 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid; 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid; 5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic Acid; MFCD00057363; NSC 203730; S.A.S. 500; C18H14N4O5S; Sulfasalazopyridine; CHEBI:9334; DTXSID0021256; Benzoic acid, 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]-; 3XC8GUZ6CB; 737754-28-8; NSC-203730; NSC-667219; S.A.S.; Azosulfidin; 2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid; 2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 2-Hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; 5-[p-(2-Pyridylsulfamoyl)phenylazo]salicylic acid; Benzoic acid, 2-hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)-; 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID; 2-hydroxy-5-(2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl)benzoic acid; Benzoic acid, 2-hydroxy-5-[2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]-; NSC203730; NSC667219; s1576; Salicylic acid, 5-((p-(2-pyridylsulfamoyl)phenyl)azo)-; NCGC00090903-01; Salazo-sulfapyridinum; CAS-599-79-1; 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid; 2-hydroxy-5-[(E)-{4-[(pyridin-2-ylamino)sulfonyl]phenyl}diazenyl]benzoic acid; 5-[p-(2-Pyridylsulfamyl)phenylazo]salicylic acid; (3Z)-6-Oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; DTXCID401256; Sulfasalazinum [INN-Latin]; Sulfasalazina [INN-Spanish]; Salicylic acid, 5-[[p-(2-pyridylsulfamoyl)phenyl]azo]-; 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid; Salazosulfapyridinum [INN-Latin]; Salazosulfapiridina [INN-Spanish]; SI-88; 2-Hydroxy-5-[(1E)-2-[4-[(2-pyridinylamino)sulfonyl]phenyl]diazenyl]benzoic acid; Azulfidine (TN); SAS; SMR000059146; Sulphasalazine, N-; CCRIS 4713; HSDB 3395; 13gs; 5-(p-(2-Pyridylsulfamoyl)phenylazo)salicylic acid; SR-05000001721; EINECS 209-974-3; UNII-3XC8GUZ6CB; Sulfasalazine (USP/INN); BRN 0356241; Iwata; Sulfasalazine RS; 2-hydroxy-5-({4-[(2-pyridylamino)sulfonyl]phenyl}diazenyl)benzoic acid; 2-Hydroxy-5-{{4-[(2-pyridinylamino)sulfonyl]phenyl}azo}benzoic acid; Sulfasalazine CRS; Prestwick_848; Sulfasalazine [USAN:USP:INN:BAN]; Spectrum_000998; Sulfasalazine (Standard); Prestwick0_000520; Prestwick1_000520; Prestwick2_000520; Prestwick3_000520; Spectrum2_001216; Spectrum3_001364; Spectrum4_000347; Spectrum5_001443; Sulfasalazine (Azulfidine); SULFASALAZINE [MI]; CHEMBL421; Epitope ID:122672; SULFASALAZINE [INN]; SCHEMBL4514; SCHEMBL4515; Salazosulfapyridine (JP18); SULFASALAZINE [HSDB]; SULFASALAZINE [IARC]; SULFASALAZINE [USAN]; SCHEMBL18490; BSPBio_000479; BSPBio_002888; KBioGR_000753; KBioGR_002314; KBioSS_001478; KBioSS_002316; SULFASALAZINE [VANDF]; 5-22-08-00433 (Beilstein Handbook Reference); MLS000759399; MLS001424109; MLS006011702; BIDD:GT0161; DivK1c_000860; SPECTRUM1500552; SULFASALAZINE [MART.]; SPBio_001032; SPBio_002400; SULFASALAZINE [USP-RS]; SULFASALAZINE [WHO-DD]; SULFASALAZINE [WHO-IP]; BPBio1_000527; CHEMBL100848; CHEMBL242373; GTPL4840; orb1224519; orb1310181; SCHEMBL1079598; SCHEMBL1229516; SCHEMBL10289061; SCHEMBL29861725; SCHEMBL31174674; SCHEMBL31296204; CHEBI:94500; HMS502K22; KBio1_000860; KBio2_001478; KBio2_002314; KBio2_004046; KBio2_004882; KBio2_006614; KBio2_007450; KBio3_002108; KBio3_002794; SALAZOSULFAPYRIDINE [JAN]; cMAP_000018; NCEXYHBECQHGNR-QZQOTICOSA-N; NINDS_000860; OQANPHBRHBJGNZ-BKUYFWCQSA-N; OQANPHBRHBJGNZ-UHFFFAOYSA-N; GLXC-07725; HMS1569H21; HMS1921C05; HMS2051J21; HMS2090P13; HMS2092K07; HMS2096H21; HMS2232H07; HMS3370D16; HMS3393J21; HMS3655G07; HMS3713H21; HMS3871J13; HMS3884E21; HMS5079K16; Pharmakon1600-01500552; SULFASALAZINE [ORANGE BOOK]; ALBB-033361; MSK10667; SULFASALAZINE [EP MONOGRAPH]; Tox21_111037; Tox21_201239; Tox21_300541; BDBM50097125; BDBM50103596; CCG-39145; DL-510; EBC-04435; HY-14655R; NSC757330; s8247; SBB058178; SULFASALAZINE [USP MONOGRAPH]; SULFASALAZINUM [WHO-IP LATIN]; AKOS002311709; AKOS025116975; AKOS026749974; AKOS037515748; Tox21_111037_1; WLN: T6NJ BSWMR DNUNR DQ CVQ; AS27942; CCG-100987; DB00795; HS-0062; NC00237; NSC-757330; IDI1_000860; SMP2_000059; NCGC00016518-01; NCGC00090903-02; NCGC00090903-03; NCGC00090903-04; NCGC00090903-05; NCGC00090903-06; NCGC00090903-07; NCGC00090903-08; NCGC00090903-09; NCGC00090903-11; NCGC00090903-12; NCGC00090903-21; NCGC00186644-01; NCGC00254313-01; NCGC00258791-01; AC-20497; HY-14655; PD087097; SMR004703430; SY052318; SBI-0051526.P003; DB-017797; NS00011872; S0580; ST50767935; SW196979-4; T0907; C07316; D00448; EN300-119546; H10652; AB00052101-04; AB00052101-06; AB00052101_07; AB00052101_08; F358095; F806146; Q420035; SR-05000001721-1; SR-05000001721-2; SR-05000001721-3; Sulfasalazine, analytical standard, >=98% (HPLC); BRD-K10670311-001-06-4; BRD-K10670311-001-08-0; BRD-K10670311-001-14-8; BRD-K10670311-001-15-5; Q27166356; Q63398427; F2173-1125; Z1521554012; 2-hydroxy-5-[4-(2-pyridylsulfamoyl)phenyl]azo-benzoic acid; 4-(Pyridyl-2-amidosulfonyl)-3''-carboxy-4''-hydroxyazobenzene; Sulfasalazine, European Pharmacopoeia (EP) Reference Standard; 2-hydroxy-5-[(E)-[4-(2-pyridylsulfamoyl)phenyl]azo]benzoic acid; 5-{4-[(2-pyridylideneamino)sulfonyl]phenyldiazenyl}salicylic acid; Sulfasalazine, United States Pharmacopeia (USP) Reference Standard; 2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-Hydroxy-5-((4-[(2-pyridinylamino)sulfonyl]phenyl)diazenyl)benzoic acid #; 2-Hydroxy-5-({4-[(pyridin-2-yl)sulfamoyl]phenyl}diazenyl)benzoic acid; 2-hydroxy-5-{(E)-[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 2-HYDROXY-5-((4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)AZO)BENZOIC ACID [WHO-IP]; 2-hydroxy-5-[(1E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid; 6-oxo-3-(2-[4-(n-pyridin-2-ylsulfamoyl)phenyl]hydrazono)cyclohexa-1,4-dienecarboxylic acid; 6-oxo-3-((4-(pyridin-2-ylsulfamoyl)phenyl) hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; 6-oxo-3-[[4-(2-pyridinylsulfamoyl)phenyl]hydrazinylidene]-1-cyclohexa-1,4-dienecarboxylic acidSinónimos
Productos que contienen Sulfasalazine
사조핀정 (설파살라진)(수출용)아자설판장용정250밀리그램(설파살라진)(수출용)아자설판장용정500밀리그램(설파살라진(살라조설파피리딘))(수출용)사피루진이엔정500(설파살라진)(수출용)조피린장용정(설파살라진)サラゾピリン坐剤500mgサラゾスルファピリジン腸溶錠250mg「NIG」/サラゾスルファピリジン腸溶錠500mg「NIG」サラゾスルファピリジン腸溶錠250mg「CH」(旧製品:処方変更前、使用期限2026年11月まで)/サラゾスルファピリジン腸溶錠500mg「CH」サラゾスルファピリジン腸溶錠250mg「CH」/サラゾスルファピリジン腸溶錠500mg「CH」アザルフィジンEN錠250mg/アザルフィジンEN錠500mgサラゾピリン錠500mgSALAZOPYRINA 500 MG COMPRIMIDOS
Página 1 de 3
Empresas que venden Sulfasalazine
한림
한림제약(주)Republic of Korea(주
(주)비씨월드제약Republic of KoreaSI
Sinoway Industrial Co.Ltd.ChinaNN
NINGBO NUOBAI PHARMACEUTICAL CO., LTD.ChinaWH
Wuxi Hexia Chemical CompanyChinaLP
Liaoning Pharmaceutical Innovation Co.. Ltd.ChinaTE
TIANJIN ENJU BIOTECHNOLOGY CO., LTD.ChinaPágina 1 de 3